Reuters logo
BRIEF-Neuren Pharmaceuticals secures funding for key activities for Rett syndrome
June 29, 2017 / 1:39 AM / in 4 months

BRIEF-Neuren Pharmaceuticals secures funding for key activities for Rett syndrome

June 29 (Reuters) - Neuren Pharmaceuticals Ltd

* Secured funding to enable initiation of key activities on critical path for commencing a phase 3 trial in rett syndrome

* Placement of new ordinary shares raising A$11.5 million at 6.2 cents per share Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below